Neurocrine Biosciences Q3 2026 Revenue Jumps 41% to $1.1 Billion
Neurocrine Biosciences posted strong third-quarter growth driven by INGREZZA sales, prompting the company to raise its full-year revenue guidance.
Neurocrine Biosciences reported total third-quarter 2026 revenue of $1.1 billion, a 41% increase compared with the same period a year earlier, the San Diego-based pharmaceutical company announced Monday. The results reflect continued momentum for its flagship product as the firm moves deeper into the second half of its fiscal year.
The company raised its full-year 2026 net sales guidance for INGREZZA, the brand name for valbenazine, to a range of $2.9 billion to $2.925 billion. The upward revision signals management confidence in sustained demand for the drug, which treats tardive dyskinesia, a movement disorder often caused by long-term use of certain psychiatric medications.
Read more Thornburg Income Builder Trust Sets $0.10417 Monthly Distribution →
Neurocrine trades on the Nasdaq exchange under the ticker symbol NBIX. The quarterly results were disclosed in a press release issued through PRNewswire ahead of market open. Analysts tracking the company had been watching INGREZZA sales closely as a primary indicator of the company's commercial health and pipeline investment capacity.
The combination of a significant year-over-year revenue surge and an upward guidance revision places Neurocrine among biopharmaceutical companies demonstrating durable top-line growth in the current market environment. Whether the trajectory continues will likely depend on competitive dynamics in the tardive dyskinesia treatment space and the company's ability to advance additional pipeline assets.
Continue reading at Earnings.
